DIVIS LABORATORIES Financial Statement Analysis
|
||
The Revenues of DIVIS LABORATORIES have increased by 28.56% YoY .
The Earnings Per Share (EPS) of DIVIS LABORATORIES has decreased by -38.41 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
DIVIS LABORATORIES Last 5 Annual Financial Results
[BOM: 532488|NSE : DIVISLAB]
Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
---|---|---|---|---|---|
Revenues | ₹8,960 Cr | ₹6,969 Cr | ₹5,394 Cr | ₹4,946 Cr | ₹3,891 Cr |
Expenses | ₹5,079 Cr | ₹4,108 Cr | ₹3,571 Cr | ₹3,073 Cr | ₹2,629 Cr |
Operating Profit (Excl OI) | ₹3,881 Cr | ₹2,861 Cr | ₹1,823 Cr | ₹1,873 Cr | ₹1,263 Cr |
Other Income | ₹116 Cr | ₹63 Cr | ₹190 Cr | ₹156 Cr | ₹113 Cr |
Interest | ₹2.00 Cr | ₹2.10 Cr | ₹7.14 Cr | ₹4.68 Cr | ₹2.37 Cr |
Depreciation | ₹312 Cr | ₹256 Cr | ₹186 Cr | ₹169 Cr | ₹142 Cr |
Profit Before Tax | ₹3,684 Cr | ₹2,666 Cr | ₹1,819 Cr | ₹1,855 Cr | ₹1,231 Cr |
Profit After Tax | ₹2,960 Cr | ₹1,984 Cr | ₹1,377 Cr | ₹1,353 Cr | ₹877 Cr |
Consolidated Net Profit | ₹2,960 Cr | ₹1,984 Cr | ₹1,377 Cr | ₹1,353 Cr | ₹877 Cr |
Earnings Per Share (Rs) | ₹68.69 | ₹111.53 | ₹74.75 | ₹51.86 | ₹50.96 |
PAT Margin (%) | 23.32 | 32.94 | 28.38 | 25.23 | 27.15 |
ROE(%) | 14.89 | 28.16 | 23.90 | 19.30 | 21.00 |
ROCE(%) | 19.36 | 35.06 | 32.07 | 25.36 | 28.50 |
Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
Key Financials |
||
Market Cap | : | ₹ 104,360.1 Cr |
Revenue (TTM) | : | ₹ 7,492.8 Cr |
Net Profit(TTM) | : | ₹ 1,383.0 Cr |
EPS (TTM) | : | ₹ 52.1 |
P/E (TTM) | : | 75.5 |
Industry Peers & Returns | 1W | 1M | 1Y |
DIVIS LABORATORIES | 3.7% | 5.8% | 17.3% |
SUN PHARMACEUTICAL INDUSTRIES | 2% | -0.3% | 59.8% |
CIPLA | 6% | 2.8% | 50.4% |
DR REDDYS LABORATORIES | -1.3% | -2.8% | 31.5% |
ZYDUS LIFESCIENCES | 2.6% | 7.9% | 94.3% |
MANKIND PHARMA | -6.5% | -7.6% | 57% |
TORRENT PHARMACEUTICALS | 3.9% | 7.3% | 60.6% |
LUPIN | 3.2% | 3.3% | 111.9% |
AUROBINDO PHARMA | 2.8% | 6.8% | 89.9% |
DIVIS LABORATORIES Revenues
[BOM: 532488|NSE : DIVISLAB]
Y-o-Y | 28.56 % |
5 Yr CAGR | 23.18 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2023 | ₹8,960 Cr | 28.56 | |
Mar2022 | ₹6,969 Cr | 29.20 | |
Mar2021 | ₹5,394 Cr | 9.06 | |
Mar2020 | ₹4,946 Cr | 27.10 | |
Mar2019 | ₹3,891 Cr | - |
DIVIS LABORATORIES Operating Profit
[BOM: 532488|NSE : DIVISLAB]
Y-o-Y | 35.65 % |
5 Yr CAGR | 32.41 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2023 | ₹3,881 Cr | 35.65 | |
Mar2022 | ₹2,861 Cr | 56.92 | |
Mar2021 | ₹1,823 Cr | -2.66 | |
Mar2020 | ₹1,873 Cr | 48.33 | |
Mar2019 | ₹1,263 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | 5.53 % |
5 Yr CAGR | 7.49 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2023 | 43.32% | 5.53 | |
Mar2022 | 41.05% | 21.45 | |
Mar2021 | 33.8% | -10.75 | |
Mar2020 | 37.87% | 16.70 | |
Mar2019 | 32.45% | - |
DIVIS LABORATORIES Profit After Tax
[BOM: 532488|NSE : DIVISLAB]
Y-o-Y | 49.19 % |
5 Yr CAGR | 35.55 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2023 | ₹2,960 Cr | 49.19 | |
Mar2022 | ₹1,984 Cr | 44.15 | |
Mar2021 | ₹1,377 Cr | 1.76 | |
Mar2020 | ₹1,353 Cr | 54.24 | |
Mar2019 | ₹877 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | -29.20 % |
5 Yr CAGR | -3.73 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2023 | 23.32 % | -29.20 | |
Mar2022 | 32.94 % | 16.07 | |
Mar2021 | 28.38 % | 12.49 | |
Mar2020 | 25.23 % | -7.07 | |
Mar2019 | 27.15 % | - |
DIVIS LABORATORIES Earnings Per Share (EPS)
[BOM: 532488|NSE : DIVISLAB]
Y-o-Y | -38.41 % |
5 Yr CAGR | 7.75 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2023 | ₹69 | -38.41 | |
Mar2022 | ₹112 | 49.20 | |
Mar2021 | ₹75 | 44.14 | |
Mar2020 | ₹52 | 1.77 | |
Mar2019 | ₹51 | - |
DIVIS LABORATORIES Return on Capital Employed (ROCE)
[BOM: 532488|NSE : DIVISLAB]
Y-o-Y | -44.78 % |
5 Yr CAGR | -9.21 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2023 | 19.36% | -44.78 | |
Mar2022 | 35.06% | 9.32 | |
Mar2021 | 32.07% | 26.46 | |
Mar2020 | 25.36% | -11.02 | |
Mar2019 | 28.5% | - |
DIVIS LABORATORIES Share Price vs Sensex
Current Share Price | : | ₹3,930.7 |
Current MarketCap | : | ₹ 104,360.1 Cr |
Updated EOD on | : | May 16,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
DIVIS LABORATORIES | 3.7% |
5.8% |
17.3% |
SENSEX | 1.7% |
-0.8% |
19% |
DIVIS LABORATORIES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE DIVIDEND STABILITY | 3.7% | 2.2% | 53.7% |
S&P BSE HEALTHCARE | 3% | 0.4% | 52.9% |
S&P BSE ALLCAP | 3% | 1% | 36% |
S&P BSE 500 | 2.9% | 0.9% | 34.2% |
MFG | 2.8% | 0.9% | 38.4% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY HEALTHCARE | 3.5% | 0.2% | 50.4% |
NIFTY 100 EQUAL WEIGHT | 3.5% | 2.2% | 47.2% |
NIFTY LARGE MIDCAP 250 | 3.4% | 1.6% | 41.7% |
NIFTY500 MULTICAP 50:25:25 | 3.2% | 1.3% | 43% |
NIFTY200 QUALITY30 | 3.2% | 1.9% | 28.4% |
You may also like the below Video Courses
FAQ about DIVIS LABORATORIES Financials
How the annual revenues of DIVIS LABORATORIES have changed ?
The Revenues of DIVIS LABORATORIES have increased by 28.56% YoY .
How the Earnings per Share (EPS) of DIVIS LABORATORIES have changed?
The Earnings Per Share (EPS) of DIVIS LABORATORIES has decreased by -38.41 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs